March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25

Steve Tuplin/LinkedIn

Dec 12, 2025, 06:48

Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25

Steve Tuplin, VP, Global Disease Area Head – Hematology and ai Oncology at Roche, shared on LinkedIn:

”The contrast between my last visit at ASH 15 years ago and this year’s meeting was striking.

It gave me a profoundly valuable sense of where haematology is heading now.

I am particularly impressed by how much the standards for treating Haemophilia A have evolved in that time.

After connecting with colleagues and hearing from the wider haemophilia A community during this period, it’s clear that the conversation continues to move beyond bleeding control, and we’re collectively taking a bigger leap into tackling the broader challenges faced by people with this disease.

As my colleague John Pasi,Global Franchise Head, Haematology and Rare Blood Diseases, Product Development at Roche, says in this recent Roche article, even as science advances, people still navigate physical, emotional, and logistical hurdles that shape “daily, different, and ever-changing realities.”

We’ve seen remarkable progress in haemophilia A care in recent years. Still, its future lies in a combination of sustained innovation, personalised approaches, and dedication to meeting the evolving needs of people living with the disease.

Read John’s full perspective on how we should combine scientific excellence with a commitment to global health equity to reshape the future of care.”

Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25